2020.10.21
Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) is pleased to announce that it won the “STI for SDGs” Award for FY2020 sponsored by the Japan Science and Technology Agency (Head office: Kawaguchi-shi, Saitama, President: Michinari Hamaguchi, hereinafter referred to as “JST”).
■ Outline of the Award
Craif’s efforts in high-precision early detection of cancer by comprehensive analysis of urinary miRNA using a distinctive device received “STI for SDGs” award in FY2020. The “STI for SDGs” award is part of JST’s Future Co-creation Promotion Program, which recognizes outstanding regional efforts to solve social issues using Science, Technology and Innovation (STI).
Details of “STI for SDGs” Award
https://www.jst.go.jp/sis/co-creation/sdgs-award/
■ Comments from CEO
We were honored to receive this award in recognition of the utilization of STI, innovation, and originality of our work. Early detection of cancer and appropriate treatment are the most important issues directly related to the reduction of medical costs and extension of healthy life expectancy, which Japan, the world’s largest aging society, can initiate.
Craif will make a significant contribution to solving this problem and creating a model society with health and happiness.
■ Our Technology and Value
Craif is a startup company founded in 2018. “NANO IP™ (NANO Intelligence Platform),” enables highly accurate detection of biological material such as microRNAs, related to diseases by using non-invasively collected bodily fluids, like urine. With this innovative platform, Craif is dedicated to developing screening tests using NANO IP™ to achieve early detection of cancer and provide the best medicine for everybody.